Press release
Methicillin Resistant Staphylococcus Aureus Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)
Methicillin Resistant Staphylococcus Aureus Pipeline
Key Takeaways from the Methicillin Resistant Staphylococcus Aureus Pipeline Report
• DelveInsight's Methicillin Resistant Staphylococcus Aureus pipeline report depicts a robust space with 25+ active players working to develop 27+ pipeline therapies for Methicillin Resistant Staphylococcus Aureus treatment.
• The leading companies working in the Methicillin Resistant Staphylococcus Aureus Market include Trellis Bioscience, LegoChem Biosciences, Aptorum Group, ContraFect, Crystalgenomics, Cellics Therapeutics, MicuRx, Oxford Antibiotic Group, Destiny Pharma, TSRL, Inc., TAXIS Pharmaceuticals, Basilea Pharmaceutica, Helperby Therapeutics, Akagera Medicines, Histogen, Alphamab Co. Ltd, Biocidium Pharmaceuticals, and others.
• Promising Methicillin Resistant Staphylococcus Aureus Pipeline Therapies in the various stages of development include Linezolid (Zyvox), Vancomycin, Ceftaroline fosamil, Linezolid, Telavancin, Tigecycline, and others.
• March 2023: Henry M. Jackson Foundation for the Advancement of Military Medicine announced a study of Phase 1 & 2 clinical trials for Monovalent rAT. This study involves the use of investigational vaccines. A vaccine is a medicine that causes the body to make antibodies. Antibodies help destroy foreign substances that enter the body. The purpose of this study is to find the right dose of a new vaccine that is safe and produces a good immune response (how well your body recognizes and defends itself against harmful foreign substances). There are two Staphylococcus aureus toxoids (components or antigens) under investigation in this study; one of them is a protein known as rAT and the other is a protein known as rLukS-PV. They are being developed to see if they are effective at preventing infections caused by the bacteria Staphylococcus aureus.
• July 2023: AbbVie announced a study of Phase 3 clinical trials for Dalbavancin single dose. To determine the safety and descriptive efficacy of dalbavancin for the treatment of acute bacterial skin and skin structure infections in children, aged birth to 17 years (inclusive), known or suspected to be caused by susceptible Gram-positive organisms, including methicillin-resistant strains of Staphylococcus aureus.
Request a sample and discover the recent advances in Methicillin Resistant Staphylococcus Aureus Treatment Drugs @ Methicillin Resistant Staphylococcus Aureus Pipeline Report- https://www.delveinsight.com/report-store/methicillin-resistant-staphylococcus-aureus-mrsa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
In the Methicillin Resistant Staphylococcus Aureus pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Methicillin-Resistant Staphylococcus Aureus Infections collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Methicillin Resistant Staphylococcus Aureus Overview
Methicillin-resistant Staphylococcus aureus (MRSA) is one of the most successful modern pathogens. The same organism that lives as a commensal and is transmitted in both health-care and community settings is also a leading cause of bacteraemia, endocarditis, skin and soft tissue infections, bone and joint infections and hospital-acquired infections.
Find out more about Methicillin Resistant Staphylococcus Aureus Therapeutics Assessment @ Methicillin Resistant Staphylococcus Aureus Preclinical and Discovery Stage Products- https://www.delveinsight.com/sample-request/methicillin-resistant-staphylococcus-aureus-mrsa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Methicillin Resistant Staphylococcus Aureus Emerging Drugs Profile
• HY-004B8b: Helperby Therapeutics
• TRL1068: Trellis Bioscience
• Delpazolid (LCB01-0371): LegoChem Biosciences
Methicillin Resistant Staphylococcus Aureus Pipeline Therapeutics Assessment
There are approx. 25+ key companies which are developing the Methicillin-Resistant Staphylococcus Aureus Infections therapies. The Methicillin-Resistant Staphylococcus Aureus Infections companies which have their Methicillin-Resistant Staphylococcus Aureus Infections drug candidates in the most advanced stage, i.e. phase II include, Helperby Therapeutics.
DelveInsight's Methicillin-Resistant Staphylococcus Aureus Infections Pipeline Report covers around 27+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Methicillin-Resistant Staphylococcus Aureus Infections pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• intravenous
• Subcutaneous
• Topical.
• Molecule Type
Methicillin-Resistant Staphylococcus Aureus Infections Pipeline Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
Learn more about the emerging Methicillin Resistant Staphylococcus Aureus Pipeline Therapies @ Methicillin Resistant Staphylococcus Aureus Clinical Trials Assessment- https://www.delveinsight.com/sample-request/methicillin-resistant-staphylococcus-aureus-mrsa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Methicillin Resistant Staphylococcus Aureus Pipeline Report
• Coverage- Global
• Methicillin Resistant Staphylococcus Aureus Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Methicillin Resistant Staphylococcus Aureus Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Methicillin Resistant Staphylococcus Aureus Companies- Trellis Bioscience, LegoChem Biosciences, Aptorum Group, ContraFect, Crystalgenomics, Cellics Therapeutics, MicuRx, Oxford Antibiotic Group, Destiny Pharma, TSRL, Inc., TAXIS Pharmaceuticals, Basilea Pharmaceutica, Helperby Therapeutics, Akagera Medicines, Histogen, Alphamab Co. Ltd, Biocidium Pharmaceuticals, and others.
• Methicillin Resistant Staphylococcus Aureus Pipeline Therapies- Linezolid (Zyvox), Vancomycin, Ceftaroline fosamil, Linezolid, Telavancin, Tigecycline, and others.
Dive deep into rich insights for new drugs for Methicillin Resistant Staphylococcus Aureus Treatment, Visit @ Methicillin Resistant Staphylococcus Aureus Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/methicillin-resistant-staphylococcus-aureus-mrsa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Executive Summary
3. Methicillin-Resistant Staphylococcus Aureus Infections: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Methicillin-Resistant Staphylococcus Aureus Infections - DelveInsight's Analytical Perspective
7. Mid Stage Products (Phase II)
8. HY-004: Helperby therapeutics
9. Drug profiles in the detailed report…..
10. Early Stage Products (Phase I)
11. TRL1068: Trellis Bioscience
12. Drug profiles in the detailed report…..
13. Preclinical and Discovery Stage Products
14. EVX B1: Evaxion Biotech
15. Drug profiles in the detailed report…..
16. Inactive Products
17. Methicillin-Resistant Staphylococcus Aureus Infections Key Companies
18. Methicillin-Resistant Staphylococcus Aureus Infections Key Products
19. Methicillin-Resistant Staphylococcus Aureus Infections- Unmet Needs
20. Methicillin-Resistant Staphylococcus Aureus Infections- Market Drivers and Barriers
21. Methicillin-Resistant Staphylococcus Aureus Infections- Future Perspectives and Conclusion
22. Methicillin-Resistant Staphylococcus Aureus Infections Analyst Views
23. Methicillin-Resistant Staphylococcus Aureus Infections Key Companies
24. Appendix
For further information on the Methicillin Resistant Staphylococcus Aureus Pipeline therapeutics, reach out to Methicillin Resistant Staphylococcus Aureus Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/methicillin-resistant-staphylococcus-aureus-mrsa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Important Published Links
https://scocial-online.mn.co/posts/46864423
https://akb.tribe.so/post/behcet-s-disease-a-rare-and-chronic-inflammatory-condition-has-long-posed-c--6576dd3288d020256754898b
https://www.sutori.com/en/denny-dones?tab=profile
https://network-96590.mn.co/posts/46865392
https://lean-in-bay-area.mn.co/posts/46865790
https://network-88594.mn.co/posts/46865905
https://decide.mn.co/posts/46866036
https://jomijomig.mn.co/posts/46866708
https://constantlycheeky.mn.co/posts/46867239
https://www.vwvortex.com/members/ybhardwaj.3957496/#about
https://redline-rp.mn.co/posts/46868784
https://forum.eset.com/profile/88964-denny-dones/?tab=field_core_pfield_11
https://en.pinkoi.com/user/gg_116344212900924579142
https://dennydones9.diary.ru/
https://slideslive.com/ewkwsgtt7o?tab=about
https://dennydones.substack.com/p/behcets-syndrome-market-size-in-the?r=33xju7&utm_campaign=post&utm_medium=web
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: +91-9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/behcets-disease-market
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Methicillin Resistant Staphylococcus Aureus Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated) here
News-ID: 3330482 • Views: …
More Releases from DelveInsight Business Research LLP
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead…
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore…
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight…
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market…
More Releases for Staphylococcus
Rise In Prevalence Of Methicillin-Resistant Staphylococcus Aureus Infections: Po …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Through 2025?
In recent times, the market size of drugs for methicillin-resistant staphylococcus aureus (MRSA) has seen continuous growth. The market, which was worth $2.35 billion in 2024, is projected to expand to $2.47 billion in…
Leading Growth Driver in the Methicillin-Resistant Staphylococcus Aureus (MRSA) …
What market dynamics are playing a key role in accelerating the growth of the methicillin-resistant staphylococcus aureus (mrsa) drugs market?
The growth of the methicillin-resistant Staphylococcus aureus drugs market is expected to be fuelled by the rise in Hospital Acquired Infections (HAIs). Patients acquire these infections while being treated at a healthcare center, usually 48 hours or more post admissions. The root causes behind HAIs include contaminated medical apparatus, lax hand…
Methicillin-Resistant Staphylococcus Aureus Testing Market Size, Share, Developm …
LP INFORMATION offers a latest published report on Methicillin-Resistant Staphylococcus Aureus Testing Market Analysis and Forecast 2019-2025 delivering key insights and providing a competitive advantage to clients through a detailed report.
According to this study, over the next five years the Methicillin-Resistant Staphylococcus Aureus Testing market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million…
Staphylococcus Aureus Testing Market In-Depth Market Research Report 2027
A wide range of human clinical infection caused by Staphylococcus Aureus such as Skin, soft tissue, bacteremia, infective endocarditis and others are the major infection caused by Staphylococcus Aureus. The increased use of Staphylococcus Aureus testing in the diagnosis of staph infection grow rapidly, due to the availability of the various advanced test to screen the pathogen efficiently. There is a number of tests present in the market for Staphylococcus…
Methicillin-resistant Staphylococcus Aureus Therapeutics Pipeline Analysis 2018
MRSA infection caused by specific "staph" bacteria that is often resistant to most of antibiotic treatments. S. aureus (SA) is listed as a ‘superbug’ by U.S. Centers for Disease Control and Prevention (CDC). MRSA can either be present harmlessly on the skin (colonization) or enter the body (e.g. through broken skin) and cause an infection. The study analyzed that MRSA infection therapeutics pipeline comprises approximately 52 drug candidates in different…
Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market – Driver
Methicillin-Resistant Staphylococcus Aureus (MRSA) is a type of staphylococcus aureus, which became resistant to methicillin, amoxicillin, penicillin, oxacillin, and other such commonly used antibiotics. Staphylococcus aureus harbors on the skin and nasal passage of about one third of the world population, which comprises around 33%, as per Centers for Disease Control and Prevention (CDC) review 2015. MRSA can be classified into two types, based on mode of infection – Hospital…
